SGLT-2 Inhibitor: Difference between revisions
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Diabetes medication]] | *Type: Oral [[Diabetes medication]] | ||
*Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes | *Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes | ||
Revision as of 03:20, 18 April 2017
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule